ArticleJournal of maxillofacial and oral surgery2015
Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial.
Article in Journal of maxillofacial and oral surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Interventions for managing oral submucous fibrosis.The Cochrane database of systematic reviews · 2024Pooled it
- Evaluating the Oral-Health-Related Quality of Life of Oral Submucous Fibrosis Patients before and after Treatment Using the OHIP-14 Tool.International journal of environmental research and public health · 2022Trial
- Drug treatment for oral submucous fibrosis: an update.BMC oral health · 2023Review
- Comparison of triamcinolone with pentoxifylline and vitamin E efficacy in the treatment of stage 2 and 3 oral submucous fibrosis: A randomized clinical trial.SAGE open medicine · 2023Article
- Comparative Efficacy of Interventions for the Management of Oral Submucous Fibrosis: A Systematic Review and Network Meta-Analysis.Journal of personalized medicine · 2022Review
- Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiological reviews · 2022Review
- Conservative management of Oral Submucous Fibrosis in early and intermediate stage.Journal of oral biology and craniofacial researchArticle
- Medicinal management of oral submucous fibrosis in the past decade- A systematic review.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAs far as research regarding any disease is concerned, each and every aspect poses a challenge. One such entity that poses a challenge in our arena is oral submucous fibrosis (OSF) as no effective treatment is available for this progressively disabling condition with high malignant potential. Hence the present study was undertaken with the aim to determine the use of pentoxifylline (PTX) on the clinical and histopathologic course of OSF.
methodThirty clinically confirmed OSF patients were categorized randomly into group I and group II. In group I, drug PTX was administered as an adjunct along with other conventional therapies. Group II patients were advised conventional therapies only. Pre- and post-treatment biopsies were obtained for the following parameters:Micro-vascular density (MVD),Area percentage of blood vessels,Severity of fibrosis, andInflammatory components.
resultsOn comparing MVD in groups I and II there was no significant difference in pre- and post-treatment.On comparing the average area percentage occupied by blood vessels, significant difference was seen in pre- and post-treatment biopsies in group I.On assessment of mouth opening and tongue protrusion, there was no significant improvement in either of the groups individually or in comparison. But when burning sensation of mucosa was assessed, pre- and post-treatment, both groups showed quite significant improvement individually.
conclusionUse of pentoxifylline seemed to be questionable, and taking into consideration the long administration time, its use is not recommended for the treatment of OSF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.